Enhanced Genomics

Enhanced Genomics operates a digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses its proprietary GenLink 3D multi-omics platform to analyze genome folding and link disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases including autoimmune conditions. Founded in 2020 and headquartered in Cambridge, United Kingdom, Enhanced Genomics has raised approximately $19M in Series A funding from investors including BGF, Parkwalk, and Meltwind Advisory. The company leverages advances in 3D genomics and chromatin conformation capture to understand how non-coding genetic variants affect gene expression through long-range DNA interactions, addressing the challenge that most disease-associated genetic variants identified by genome-wide association studies fall outside protein-coding regions and their target genes remain unknown.